A Claim By Any Other Name - Industry Eyes More Defined Promotional Terms
This article was originally published in The Gray Sheet
Executive Summary
FDA should clarify definitions and relationships between indications for use, intended use and claims, industry representatives suggested June 14 at AdvaMed's 11th Annual Device Submissions Workshop in Washington, D.C.
You may also be interested in...
FDA Acknowledges Lack Of Clarity In Device Labeling Draft Guidance
CDRH Office of Device Evaluation officials indicate they will remove a 1997 draft guidance entitled "Medical Device Labeling - Suggested Format and Content" from the center's web page in order to clear up ambiguity over labeling terms.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.